Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

[Editor's Note: This is part two of a two-part interview. Part one appeared May 4, 2008 in PharmAsia News.]
Advertisement

Related Content

Quick Take: AstraZeneca Pursues Traditional Chinese Medicine As New Source For R&D
Novartis Lines Up $1 Billion For China R&D
Novartis Lines Up $1 Billion For China R&D
Poised To Produce A/H1N1 Vaccine, Sanofi Pasteur Ramping Up Capacity In U.S., Developing Defense For Another Killer Virus
Novartis Looks To New Models For Neglected Disease Research
Singapore Continues To Attract MNCs; Hill-Rom The Latest To Open Innovation Center In Country
Novartis Partners With Clinton Foundation, Indian And Chinese Drug Makers To Improve Access To Malaria Drugs
Novartis’ Enablex Given Green Light for Clinical Trials By China’s SFDA
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 1 of 2)
Advertisement
UsernamePublicRestriction

Register

SC068649

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel